APGE vs XYL · $2.34B cap vs P/E 27, rev $4.46B
Apogee Therapeutics, Inc. Common Stock (APGE) versus Xylem Inc (XYL) — a side-by-side from cached financials, not a winner call.
Apogee Therapeutics, Inc. Common Stock (APGE) is a biotechnology company listed on US.
Xylem Inc (XYL) is a specialty industrial machinery company listed on NYSE.
APGE does not have a complete income-statement cache yet.
Latest reported XYL revenue for 2026-06-30 was $4.46B. Net income was $456.0M. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
APGE currently screens at market cap $2.34B. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
Not investment advice. Open the APGE and XYL stock pages for the full models.
Not investment advice.